The largest database of trusted experimental protocols

3 protocols using lmk 235

1

Pharmacological Modulation of Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
For in vitro studies: PGF2α (Cayman), rmFGF1 (Peprotech), rmPDGFBB (Peprotech), rmPDGFAA (Peprotech), rh/mWnt-5a (R&D), LPA (Santa Cruz biotech), rmIL6 (Peprotech), S1P (Cayman), Adapalene (Selleckchem), SAG (Tocris), rmTGFβ1(R&D), rmTGFβ2(R&D), rmTGFβ3 (R&D), CCL2 (BioLegend), CCR2 inhibitor (Santa Cruz Biotechnology), MEKi (PD0324901, 2 μM, Selleckchem), PI3Ki (LY294002, 2 μM, Selleckchem) , mTORi (Rapamycin, 100 nM, Selleckchem), Trametinib (Selleckchem, 50 nM), Alpelisib (Selleckchem, 5 μM) and ARS-1620 (MedChemExpress).
For in vivo studies: TGFβ neutralizing antibody (BioXCell, Clone 1D11, 200 μg, every other day, i.p), Clodronate liposome (Liposoma, 0.1 ml per 10 mg weight, every 5 days, i.p), Trametinib (Selleckchem, 0.3 or 1 or 3 mg/kg as indicated, q.d., oral), Alpelisib (Selleckchem, 50 mg/kg, once per day, oral), ARS-1620 (MedChemExpress, 200 mg/kg, q.d., oral), LMK-235 (MedChemExpress, 5 mg/kg, q.d., i.p.), Galunisertib (Selleckchem, 50 mg/kg, b.i.d., oral), mouse CCL2 neutralizing antibody (BioXCell, 5 mg/kg, every 2 days, i.p.), and RS 504393 (Cayman, 2 mg/kg, q.d., i.p.).
+ Open protocol
+ Expand
2

Murine Pancreatic Cancer Immunotherapy

Check if the same lab product or an alternative is used in the 5 most similar protocols
6-week-old C57BL/6 mice were from Charles River Laboratories (Wuhan, China). The study was approved by the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology. Panc02 cells (5 × 106 in 100 µL 1 × PBS) were injected s.c. into the right flank of mice. The volume of the allograft was calculated by the formula (L × W2 × 0.5). After the allografts reached a size of 50 mm3, mice carrying same types of tumors were divided randomly (simple randomization) into different groups and treated with anti-PD-1 (BioXcell, Clone RMP1-14) or IgG (BioXcell, Clone 2A3) with or without the co-treatment of LMK235 (MedChemExpress, HY-18998). Mice were euthanized at day 24 (mice meet the standard for euthanize before the end-day because of unexpected reasons like ulceration or infection were excluded from the analysis). Tumors were collected for flow cytometry analysis. KPC derived PDAC cells were cultured as described previously 26 (link). 105 KPC derived PDAC cells were injected orthotopically into C57BL/6 mice. Mouse was euthanized when it meets the end-point standard required by ethics committee. And the tumor was collected for immune-fluorescence and FACS.
+ Open protocol
+ Expand
3

Cell Proliferation Assays with LMK-235 and Vorinostat

Check if the same lab product or an alternative is used in the 5 most similar protocols
LMK-235(Cat# HY-18998) and Vorinostat (Cat# HY-10221) were purchased from MedChemExpress (MCE, USA). KYSE150 and TE-1 cells, treated with LMK-235 for 48 hr, were plated at 2×103 cells/well into 96-well plate in five replicates. Cell proliferation was measured using CCK-8 kit (Dojindo, Japan) at the following day (day 0) and every 24 hr after (up to day 4). Optical density (OD) was read at 450 nm by SpectraMax M5e Microplate Reader (Molecular Devices, CA, USA).
For EdU (5-Ethynyl-2´-deoxyuridine) incorporation assay, the above-mentioned cells were seeded into glass bottom dish (35 mm) at 5×104 cells/dish in triplicate. After incubation with 10 mM EdU (RiboBio Co., Ltd, China; Cat# C10310-3) for 5 hr, nuclei were counterstained with Hoechst 33342. The percentage of proliferative cells (EdU-positive) was measured within three random fields under LSM 880 confocal microscope (Carl Zeiss, Oberkochen, Germany) using 20×objective.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!